Last edition
News about "Dupixent "
Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.
Dupixent | 10/11/2025 | By Dineshwori | 119
EMA Approves Dupixent as First-Ever Targeted Therapy for Patients with COPD
The European Medicines Agency (EMA) has recently announced their approval for Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
Dupixent | 04/07/2024 | By Aishwarya | 421
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy